Financial Data and Key Metrics Changes - The company has made excellent progress in its GABAB positive allosteric modulator program, completing the R&D phase and delivering multiple drug candidates [6]. Business Line Data and Key Metrics Changes - A partner, Indivior, has selected a compound for development in substance use disorder and has initiated R&D enabling studies [6]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the available content. Company Strategy and Development Direction and Industry Competition - The company is focused on advancing its GABAB PAM preclinical program, indicating a strategic emphasis on substance use disorder treatments [6]. Management's Comments on Operating Environment and Future Outlook - Management has expressed confidence in the progress of their R&D programs and the selection of compounds for further development [6]. Other Important Information - The financial statements and press release were made available on the company's website prior to the conference call [4]. Q&A Session Summary - No specific questions and answers from the Q&A session were provided in the available content.
Addex Therapeutics(ADXN) - 2024 Q3 - Earnings Call Transcript